盐酸替罗非班治疗冠心病的效果

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (29 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the effectiveness of Tirofiban Hydrochloride in the treatment of coronary heart disease.Methods A total of 88 patients with coronary heart disease admitted to the Iron Coal General Hospital of Liaoning Health Industry Group from June 2018 to June 2020 were selected as the research objects. They were divided into a control group (44 cases) and a test group (44 cases) by the odd and even number grouping method. The control group used conventional treatment, and the test group was treated with Tirofiban Hydrochloride on the basis of conventional treatment. The treatment efficiency, cardiac function, homocysteine (Hcy), high-sensitivity C-reactive protein (hs-CRP)levels and the rate of adverse events were compared between the two groups. Results The total effective rate of the test group was higher than that of the control group, the difference was statistically significant (P＜0.05). After treatment, the output per minute, ejection fraction and stroke volume of the test group were higher than those of the control group, the differences were statistically significant (P＜0.05). The levels of Hcy and hs-CRP in the test group were lower than those in the control group, the differences were statistically significant (P＜0.05). The total incidence rate of adverse events in the test group was lower than that in the control group, the difference was statistically significant (P＜0.05).Conclusion Tirofiban Hydrochloride in the treatment of coronary heart disease can significantly improve the clinical efficacy, improve heart function, reduce the body′s inflammatory reaction, and reduce the occurrence of adverse events.

Key words： Tirofiban Hydrochloride Coronary heart disease Therapeutic effectiveness；Cardiac Function

Received: 21 August 2020

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHENG Qian-kun

Cite this article:

CHENG Qian-kun. Effect of Tirofiban Hydrochloride in the treatment of coronary heart disease[J]. 中国当代医药, 2021, 28(12): 144-146.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I12/144

[1]	武秀丽，张录平，丁玉琴，等.枣仁安神胶囊联合常规西药治疗冠心病伴焦虑抑郁的临床研究[J].中国医院用药评价与分析，2020，20（6）：648-651.
[2]	欧文森.盐酸替罗非班治疗冠心病的有效性分析[J].齐齐哈尔医学院学报，2016，37（34）：4335-4336.
[3]	蒋青峰.比伐芦定联合经皮冠状动脉介入治疗冠心病效果观察[J].中国药物与临床，2020，20（11）：1885-1887.
[4]	郑壮勋，郑成芳，陈壮荣.美托洛尔联合曲美他嗪治疗冠心病合并心力衰竭患者的临床研究[J].中国临床药理学杂志，2020，36（13）：1786-1789.
[5]	王颖，李安娜.氯吡格雷联合阿司匹林治疗冠心病患者的疗效观察[J].实用临床医药杂志，2020，24（12）：73-76.
[6]	顾永伟，许康世，朱成振，等.用盐酸替罗非班与低分子肝素治疗冠心病的效果研究[J].当代医药论丛，2017，15（22）：16-17.
[7]	陈寅，袁玉梅.盐酸替罗非班治疗冠心病的疗效及对同型半胱氨酸水平的影响[J].中国基层医药，2017，24（13）：1921-1925.
[8]	罗春生，宋丽，王月香.盐酸替罗非班应用于冠心病治疗中的疗效分析[J].哈尔滨医药，2016，36（Z1）：3-4.
[9]	杨力，熊雷，徐帅.芪参益气滴丸联合盐酸替罗非班对冠心病患者同型半胱氨酸水平的影响[J].中国医院用药评价与分析，2016，16（10）：1346-1348.
[10]	樊蓉，薛凌，高强.不同临床治疗方案在100 例冠心病高血压合并心房颤动中的效果分析[J].贵州医药，2020，44（7）：1077-1078.
[11]	李运革，庹田.依那普利联合缬沙坦治疗高血压合并冠心病的临床研究[J].中西医结合心脑血管病杂志，2020，18（12）：1950-1953.
[12]	苏钦，陈丽珺，王军华，等.益气化瘀利水方联合西药治疗冠心病经皮冠状动脉介入术后慢性心力衰竭的疗效观察[J].中国中医药科技，2020，27（4）：587-588.
[13]	高伟，陈士华.盐酸替罗非班在冠心病临床治疗中的应用研究[J].中国继续医学教育，2019，11（30）：124-126.
[14]	王亚宽.芪参益气滴丸联合盐酸替罗非班治疗冠心病对血脂、血清Hcy 及心功能的影响[J].实用中医药杂志，2017，33（12）：1401-1402.
[15]	高颖，肖冬，王辉.盐酸替罗非班在冠心病临床治疗中的应用研究[J].系统医学，2017，2（13）：56-58.